Navigation Links
At Three Months Post Launch, Two-Thirds of Surveyed U.S. Rheumatologists Believe that Initiations of Pfizer's Xeljanz in the Rheumatoid Arthritis Treatment Algorithm Will Occur Following at Least Two Biologic Failures

EXTON, Pa., April 24 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that two-thirds of surveyed U.S. rheumatologists believe that—at three months post launch—initiations of Pfizer's Xeljanz in the rheumatoid arthritis (RA) treatment algorithm will follow methotrexate failure/intolerance and at least two biologic failures. Only one in ten surveyed physicians currently plan to use the treatment prior to biologic initiation.

(Logo: )

According to the BioTrends Research Group report entitled LaunchTrends®: Xeljanz, Wave 2, surveyed rheumatologists report that among their patients currently treated with Xeljanz, 87 percent were switched from a biologic agent, while the remaining 13 percent of current Xeljanz patients were biologic naive prior to initiation. When questioned directly about agents at risk for displacement, nearly one-quarter of rheumatologists believe that Xeljanz is most likely to displace Genentech's Actemra with regard to RA patient share.

The recently published report also reveals that at three months post launch, approximately one-third of surveyed rheumatologists report prescribing Xeljanz in an average of three RA patients. Although rheumatologists anticipate Xeljanz trial rates to increase in the future, four percent claim that they will never use Xeljanz, primarily due to efficacy concerns and side effects.

"The percent of rheumatologists who have used Xeljanz in at least one patient has remained around one-third since the first wave of research, at one-month post launch," said BioTrends Research Group Associate Director of Immunology Lynn Price . "However, according to the data, Xeljanz trial rates are anticipated to double in the coming months."

LaunchTrends®: Xeljanz, Wave 2 is a four-wave syndicated report series designed to track the uptake of Xeljanz at one month, three months, six months and one year following its commercial availability based upon primary research with U.S. rheumatologists. LaunchTrends assess trial and use of new products, obstacles to use, reasons to use, typical patient types, line of therapy, product perceptions, promotional efforts/messages and product satisfaction. In the current wave of research, BioTrends surveyed 74 U.S. rheumatologists in February 2013 and conducted qualitative interviews with a subset of 15 of the respondents in March 2013.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort


SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. deCODE Genetics, in Collaboration with Academic Colleagues, Discovers Three Variants in the Sequence of the Human Genome that Affect the Risk of Thyroid Cancer
2. Aviir Laboratories Announce National Agreement with Three Rivers Provider Network
3. Origin Agritech Limited Reports Unaudited Third Quarter Financial Results For Three Months Ended June 30, 2012
4. Seahorse Bioscience Ranks No. 1600 on the Inc. 500
5. 5000 List of Fastest-Growing Private Companies in America for 2012 with Three-Year Sales Growth of 183%
6. Three Hertz Foundation Fellows Receive Presidential Honors; Leaders in Applied Physical, Biological and Engineering Sciences
7. RiboMed Receives Three Additional Patents for Disease Diagnostics Methods
8. RiboMed Receives Three Additional Patents for Disease Diagnostics Methods
9. Alpha Source, Inc. Makes Third Straight Inc. 5000 List with Three-Year Sales Growth of 53%
10. Three Blockbuster Patent Cases at the Supreme Court This Term
11. Origin Agritech Limited Reports Unaudited First Quarter Financial Results For Three Months Ended December 31, 2012
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015 Celemics, a global ... into the North American market with the establishment of ... and Europe , has secured ... Target Enrichment methodology and sample preparation for DNA sequencing ... both hereditary and somatic genetic testing more accurately, quickly, ...
(Date:10/8/2015)...  The ALS Association, in partnership with Prize4Life, is ... revolutionize communication technology solutions for people living with ALS. ... (amyotrophic lateral sclerosis) is a progressive neurodegenerative disease that ... spinal cord. Eventually, people with ALS lose the ability ... to total paralysis and death within two to five ...
(Date:10/8/2015)... ... October 08, 2015 , ... ... an exclusive license agreement to develop and commercialize intellectual property rights belonging to ... agreement from February 2009, and affords exclusive worldwide rights to intellectual property based ...
(Date:10/7/2015)... Texas (PRWEB) , ... October 07, 2015 , ... ... Institute ( ) will present a public educational seminar on the latest ... Saturday, October 10th from 1:00 pm – 3:00 pm at the Hilton Dallas/Southlake ...
Breaking Biology Technology:
... Merrimack Pharmaceuticals today announced that it will present at the Jefferies 2010 Global Life Sciences Conference ... provide a company overview at 11:00am EDT , Wednesday, June 9, 2010 at ... , , ... , , , ...
... June 1 Diplomat Specialty Pharmacy, the ... launch of Navigator Health Services, an independent division of ... pharmacy industry. The announcement was made by Diplomat Specialty ... who says that Navigator Health Services was formed in ...
... Calif. , June 1 Epeius Biotechnologies Corporation ( ... "Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Rexin-G as ... the ASCO Annual Meeting on June 8, 2010 . The ... Stanford University Medical Center, Palo Alto CA. ...
Cached Biology Technology:
(Date:9/10/2015)... , Sept. 10, 2015 Pursuant ... Clinic Wellness to create an interactive, image-based health ... health and wellness kiosk.  The unique assessment quantifies ... a number that suggests an individual,s biological age ... values as measured by the kiosk. ...
(Date:9/8/2015)... , Sept. 8, 2015   TREW Marketing ... the new survey, Smart Marketing for Engineers TM ... 580 engineering professionals reveals insightful findings about engineers, preferences ... types of content engineers most value and trust, and ... Marketers targeting technical audiences grapple with how to ...
(Date:9/2/2015)... YORK , Sept. 2, 2015 ... key concern for enterprises, banks, government organizations, telecommunications, ... and numeric keypads were previously being used to ... introduction of two-factor authentication, wherein individuals could gain ... two different components, such as hardware devices and ...
Breaking Biology News(10 mins):
... "We can make you and we can break you." If ... oxide would start something like that. But this song wouldn,t ... of Rice chemist James Tour demonstrates an environmentally friendly way ... version of single-atom-thick graphene expected to find use in all ...
... A novel approach detects genetically abnormal cells in the blood ... in tumor cells and increase in number with the severity ... The University of Texas MD Anderson Cancer Center report in ... patients in the study also had many times the number ...
... A University of Minnesota Medical School research team led ... a novel approach to ease the chronic and acute ... a mouse model of SCD, Gupta and University of ... that exhibited both musculoskeletal pain and temperature sensitivity, symptoms ...
Cached Biology News:
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
Application: For use as a carrier in nucleic acid purification and precipitation. Physical form: Solution in 10 mM Tris HCl, pH 7.4, 1 mM EDTA Concentration: 9-11 mg/mL Physical Form: buffered aqu...
... Note: Prepared by a modification of ... al., Biotechnol. Bioeng., 11 ... unit will yield an A 260 ... of water (1 cm light path). ...
... Unique, compact measuring instrument for calibrating ... compact design and the robust carrying case, ... both in the laboratory and on-site at ... easy to use because the individual channels ...
Biology Products: